CAJ | 학술논문

目的探讨醋酸钙片对血液透析(HD)高磷血症患者血钙(Ca)、磷(P)水平的影响.方法选择2012年2月至2014年2月本院收治的HD高磷血症患者64例,随机分为研究组(32例)和对照组(32例).在原有HD方案的基础上,对照组患者采用碳酸钙片治疗,研究组患者采用醋酸钙片治疗.结果研究组治疗4周、治疗8周时P及CaP乘积显著降低,与治疗前相比差异具有统计学意义(P＜0.05);且治疗8周时P及CaP乘积显著低于对照组(P＜0.05).两组Ca、iPTH水平对比差异无统计学意义(P＞0.05).研究组药物不良反应发生率为18.75％,对照组为21.86％,两组患者不良反应症状均较轻微,减药或停药后症状完全消失.结论醋酸钙片可以有效控制HD高磷血症患者体内的P水平,且对Ca无明显影响,大大降低了高钙血症的发生机率,疗效确切,安全性佳,适于临床推广与应用.
목적 탐토작산개편대혈액투석(HD)고린혈증환자혈개(Ca)、린(P)수평적영향.방법 선택2012년2월지2014년2월본원수치적HD고린혈증환자64례,수궤분위연구조(32례)화대조조(32례).재원유HD방안적기출상,대조조환자채용탄산개편치료,연구조환자채용작산개편치료.결과 연구조치료4주、치료8주시P급CaP승적현저강저,여치료전상비차이구유통계학의의(P＜0.05);차치료8주시P급CaP승적현저저우대조조(P＜0.05).량조Ca、iPTH수평대비차이무통계학의의(P＞0.05).연구조약물불량반응발생솔위18.75％,대조조위21.86％,량조환자불량반응증상균교경미,감약혹정약후증상완전소실.결론 작산개편가이유효공제HD고린혈증환자체내적P수평,차대Ca무명현영향,대대강저료고개혈증적발생궤솔,료효학절,안전성가,괄우림상추엄여응용.
Objectives To investigate influence of Ca,P levels of Calcium Acetate Tablets on hemodialysis patients with hyperphosphatemia.Methods Selected 64 HD patients with hyperphosphatemia in 2012 February ～2014 February in our hospital,which were randomly divided into the study group(32 cases) and control group (32 cases).On the basis of the original HD scheme,the control group was treated with Calcium Carbonate Tablets treatment,the study group was trcated with Calcium Acetate Tablets treatment.Results For 4 weeks,8 weeks of treatment,P and CaP product in the study group were significantly reduced than before treatment,the difference was statistically significant (P ＜0.05);and the 8 weeks of treatment P and CaP product was significantly lower than the control group(P ＜ 0.05).The two groups had no statistically significant difference between Ca,iPTH levels (P ＞0.05).The incidence of adverse reaction of study group was 18.75％,the incidence of adverse reaction of control group 28.13％,two groups of patients with adverse reactions were mild.Conclusions Calcium Acetate Tablets can effectively control HD hyperphosphatemia in patients with the level of P in vivo,and had no significant effect on Ca,reduced the incidence of hypercalcemia,efficacy,safety,and it is suitable for clinical popularization and application.